Abstract: Provided is a method for detecting miRNA-206 for analyzing the diagnosis or prognosis of a mental illness by a mood disorder, a method for providing information for the diagnosis, and a composition for targeting miRNA-206, more specifically, the present invention can detect diagnosis or prognostic analysis marker of the said mental illness by a mood disorder, enable a more accurate diagnosis of a mental illness by a mood disorder by measuring the expression level of miR-206 from a tissue sample of a patient, provide a diagnostic composition capable of measuring the expression level of the said miR-206, and furthermore provide a pharmaceutical composition capable of treating and preventing a mental illness by a mood disorder by using an oligonucleotide that can bind complementary to microRNA-206.

Abstract: Provided is an information providing method including the steps of acquiring a biological sample separated from a specimen, identifying concentration of a protein, TNF-related apoptosis-inducing ligand (TRAIL) in the cerebrospinal fluid from the said biological sample, comparing the concentration of the said identified TRAIL to a reference value, and providing information related to encephalitis disorder according to the said results of comparison.

Abstract: Provided is a mixture containing D-serine and caffeine as an active ingredient for obtaining the effect of preventing the decline of learning ability or memory caused by stress, reducing the influence of stress and enhancing learning ability or memory, and to provide a functional food composition containing the same.

Abstract: The present invention relates to a method for detecting miRNA-206 for analyzing the diagnosis or prognosis of a mental illness by a mood disorder, a method for providing information for the diagnosis, and a composition for targeting miRNA-206, more specifically, the present invention can detect diagnosis or prognostic analysis marker of the said mental illness by a mood disorder, enable a more accurate diagnosis of a mental illness by a mood disorder by measuring the expression level of miR-206 from a tissue sample of a patient, provide a diagnostic composition capable of measuring the expression level of the said miR-206, and furthermore provide a pharmaceutical composition capable of treating and preventing a mental illness by a mood disorder by using an oligonucleotide that can bind complementary to microRNA-206.

Abstract: Provided is a method for diagnosis of Alzheimer's disease or mild cognitive impairment. The method for diagnosis of Alzheimer's disease or mild cognitive impairment of the present invention identifies expression level of miR-206 of olfactory tissue, by which shows high diagnostic rate in diagnosis of Alzheimer's disease and mild cognitive impairment, allowing diagnosis at low cost and biopsy in high stability to lead a marked effect on diagnosis of Alzheimer's disease or mild cognitive impairment.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases by targeting a specific miRNA. In addition, the present invention relates to a kit for diagnosing neurodegenerative diseases. A miR-206 target found in the present invention, which is highly expressed in both animal models of Alzheimer's disease and human brain samples, is a substantial treatment target selected without artifact errors. An antisense oligonucleotide of the present invention as an inhibitor for miR-206 suggests a successful result in treatment of neurodegenerative diseases by targeting miRNA. The antisense oligonucleotide of the present invention inhibits the function of miR-206 to greatly increase the levels of BDNF and IGF-1 and to increase the regeneration of synapses, thereby treating neurodegenerative diseases, particularly Alzheimer's disease.

Abstract: The present disclosure provides adipose cell extracts and its use. The composition comprising the present extracts and method can be used advantageously for a stem cell-based, noninvasive therapy for treating neurologic disease such as stroke and HD. Also, in contrast to the stem cell transplantation, the present method or composition enables the repeated treatments, due to the convenient administration, thus leading to a more efficient prevention and/or curing of the disease of interest.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases by targeting a specific miRNA. In addition, the present invention relates to a kit for diagnosing neurodegenerative diseases. A miR-206 target found in the present invention, which is highly expressed in both animal models of Alzheimer's disease and human brain samples, is a substantial treatment target selected without artifact errors. An antisense oligonucleotide of the present invention as an inhibitor for miR-206 suggests a successful result in treatment of neurodegenerative diseases by targeting miRNA. The antisense oligonucleotide of the present invention inhibits the function of miR-206 to greatly increase the levels of BDNF and IGF-1 and to increase the regeneration of synapses, thereby treating neurodegenerative diseases, particularly Alzheimer's disease.

Abstract: Disclosed is a method for treating olfactory disorders, which comprises administering to a patient a therapeutically effective amount of 3-?-hydroxymethylglutarate CoA (HMG-CoA) reductase, which has excellent effects of protecting and regenerating olfactory nerve.

Abstract: Disclosed is a composition for treating olfactory disorders, the composition comprising at least one statin-like drug, which is an HMG-CoA reductase inhibitor, as an active ingredient. The composition has excellent effects of protecting and regenerating olfactory nerve.